clinical trial · NCT04609566
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Seagen, a wholly owned subsidiary of Pfizer·phase2·completed·n = 161
MelanomaNon-small Cell Lung CancerSquamous Cell Carcinoma of the Head and Neckbrentuximab vedotinpembrolizumab
brief summary
This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial. The cancer must have spread to other parts of the body (metastatic). The study will also find out what side effects occur. A side effect is anything the treatment does besides treat cancer. This is a multi-cohort study.
started
Jan 26, 2021
primary completion
Feb 3, 2026
completion
Feb 3, 2026
last updated
Jul 6, 2026
official title
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Participants With Metastatic Solid Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol